Annual Changes to the Nasdaq Biotechnology Index

Rhea-AI Summary

On December 11, 2020, Nasdaq (NDAQ) announced the reconstitution of the Nasdaq Biotechnology Index (NBI), effective December 21, 2020. This annual adjustment will include 100 new biotech and pharmaceutical securities, enhancing the index's representation in the sector. Notable additions are Arbutus Biopharma, Adaptimmune Therapeutics, and BioNTech, among others. Conversely, 16 securities will be removed from the index, including ADMA Biologics and Myris, Inc. The changes aim to better reflect market trends and advance investor insights into the biotech landscape.

Positive

• Inclusion of 100 new securities enhances the diversity of the Nasdaq Biotechnology Index.
• Notable additions include established companies like BioNTech, which could attract more investor interest.

Negative

• Removal of 16 companies may indicate weakened performance or reduced investor confidence in those securities.
• Potential volatility for stocks that are being removed from the index, affecting their market perception.

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 100 securities will be added to the Index:

EXCHANGE	SYMBOL	COMPANY NAME
Nasdaq	ABUS	Arbutus Biopharma Corporation
Nasdaq	ADAP	Adaptimmune Therapeutics plc
Nasdaq	AKUS	Akouos, Inc.
Nasdaq	ALT	Altimmune, Inc.
Nasdaq	ALVR	AlloVir, Inc.
Nasdaq	ALXO	ALX Oncology Holdings Inc.
Nasdaq	AMTI	Applied Molecular Transport Inc.
Nasdaq	ANNX	Annexon, Inc.
Nasdaq	APLT	Applied Therapeutics, Inc.
Nasdaq	APRE	Aprea Therapeutics, Inc.
Nasdaq	ARCT	Arcturus Therapeutics Holdings Inc.
Nasdaq	ARQT	Arcutis Biotherapeutics, Inc.
Nasdaq	AVDL	Avadel Pharmaceuticals plc
Nasdaq	AZN	AstraZeneca PLC
Nasdaq	BDTX	Black Diamond Therapeutics, Inc.
Nasdaq	BEAM	Beam Therapeutics Inc.
Nasdaq	BNTX	BioNTech SE
Nasdaq	CABA	Cabaletta Bio, Inc.
Nasdaq	CALA	Calithera Biosciences, Inc.
Nasdaq	CDXS	Codexis, Inc.
Nasdaq	CLVS	Clovis Oncology, Inc.
Nasdaq	CNCE	Concert Pharmaceuticals, Inc.
Nasdaq	CNST	Constellation Pharmaceuticals, Inc.
Nasdaq	CRNX	Crinetics Pharmaceuticals, Inc.
Nasdaq	CRTX	Cortexyme, Inc.
Nasdaq	FMTX	Forma Therapeutics Holdings, Inc.
Nasdaq	FPRX	Five Prime Therapeutics, Inc.
Nasdaq	FREQ	Frequency Therapeutics, Inc.
Nasdaq	FULC	Fulcrum Therapeutics, Inc.
Nasdaq	FUSN	Fusion Pharmaceuticals Inc.
Nasdaq	GBIO	Generation Bio Co.
Nasdaq	GMDA	Gamida Cell Ltd.
Nasdaq	HARP	Harpoon Therapeutics, Inc.
Nasdaq	IDYA	IDEAYA Biosciences, Inc.
Nasdaq	IGMS	IGM Biosciences, Inc.
Nasdaq	IMAB	I-MAB
Nasdaq	IMUX	Immunic, Inc.
Nasdaq	IMVT	Immunovant, Inc.
Nasdaq	INZY	Inozyme Pharma, Inc.
Nasdaq	ISEE	IVERIC bio, Inc.
Nasdaq	ITOS	iTeos Therapeutics, Inc.
Nasdaq	JNCE	Jounce Therapeutics, Inc.
Nasdaq	KALA	Kala Pharmaceuticals, Inc.
Nasdaq	KALV	KalVista Pharmaceuticals, Inc.
Nasdaq	KDMN	Kadmon Holdings, Inc.
Nasdaq	KDNY	Chinook Therapeutics, Inc.
Nasdaq	KLDO	Kaleido Biosciences, Inc.
Nasdaq	KMDA	Kamada Ltd.
Nasdaq	KNSA	Kiniksa Pharmaceuticals, Ltd.
Nasdaq	KROS	Keros Therapeutics, Inc.
Nasdaq	KRYS	Krystal Biotech, Inc.
Nasdaq	KZR	Kezar Life Sciences, Inc.
Nasdaq	LEGN	Legend Biotech Corporation
Nasdaq	LRMR	Larimar Therapeutics, Inc.
Nasdaq	MDGL	Madrigal Pharmaceuticals, Inc.
Nasdaq	MNOV	MediciNova, Inc.
Nasdaq	MRNS	Marinus Pharmaceuticals, Inc.
Nasdaq	MRSN	Mersana Therapeutics, Inc.
Nasdaq	NK	NantKwest, Inc.
Nasdaq	NKTX	Nkarta, Inc.
Nasdaq	NLTX	Neoleukin Therapeutics, Inc.
Nasdaq	NRIX	Nurix Therapeutics, Inc.
Nasdaq	NVAX	Novavax, Inc.
Nasdaq	NXTC	NextCure, Inc.
Nasdaq	OCUL	Ocular Therapeutix, Inc.
Nasdaq	ODT	Odonate Therapeutics, Inc.
Nasdaq	ORIC	Oric Pharmaceuticals, Inc.
Nasdaq	OVID	Ovid Therapeutics Inc.
Nasdaq	PAHC	Phibro Animal Health Corporation
Nasdaq	PAND	Pandion Therapeutics Inc.
Nasdaq	PASG	Passage Bio, Inc.
Nasdaq	PCVX	Vaxcyte, Inc.
Nasdaq	PLRX	Pliant Therapeutics, Inc.
Nasdaq	PRTK	Paratek Pharmaceuticals, Inc.
Nasdaq	PRVB	Provention Bio, Inc.
Nasdaq	PSTX	Poseida Therapeutics, Inc.
Nasdaq	RAPT	RAPT Therapeutics, Inc.
Nasdaq	RDHL	Redhill Biopharma Ltd.
Nasdaq	REPL	Replimune Group, Inc.
Nasdaq	RLAY	Relay Therapeutics, Inc.
Nasdaq	RLMD	Relmada Therapeutics, Inc.
Nasdaq	RNA	Avidity Biosciences, Inc.
Nasdaq	RPRX	Royalty Pharma plc
Nasdaq	RPTX	Repare Therapeutics Inc.
Nasdaq	RVMD	Revolution Medicines, Inc.
Nasdaq	SELB	Selecta Biosciences, Inc.
Nasdaq	SMMT	Summit Therapeutics Inc.
Nasdaq	SNDX	Syndax Pharmaceuticals, Inc.
Nasdaq	SPRO	Spero Therapeutics, Inc.
Nasdaq	STRO	Sutro Biopharma, Inc.
Nasdaq	SURF	Surface Oncology, Inc.
Nasdaq	SWTX	SpringWorks Therapeutics, Inc.
Nasdaq	TCRR	TCR2 Therapeutics Inc.
Nasdaq	VIE	Viela Bio, Inc.
Nasdaq	VIR	Vir Biotechnology, Inc.
Nasdaq	VSTM	Verastem, Inc.
Nasdaq	VYNE	VYNE Therapeutics Inc.
Nasdaq	XENE	Xenon Pharmaceuticals Inc.
Nasdaq	ZIOP	ZIOPHARM Oncology Inc
Nasdaq	ZNTL	Zentalis Pharmaceuticals, Inc.

As a result of the reconstitution, the following 16 securities will be removed from the Index:

EXCHANGE	SYMBOL	COMPANY NAME
Nasdaq	ADMA	ADMA Biologics Inc
Nasdaq	AMRS	Amyris, Inc.
Nasdaq	AXNX	Axonics Modulation Technologies, Inc.
Nasdaq	CERS	Cerus Corporation
Nasdaq	CRBP	Corbus Pharmaceuticals Holdings, Inc.
Nasdaq	EOLS	Evolus, Inc.
Nasdaq	EYPT	EyePoint Pharmaceuticals, Inc.
Nasdaq	GLYC	GlycoMimetics, Inc.
Nasdaq	GRTS	Gritstone Oncology, Inc.
Nasdaq	LXRX	Lexicon Pharmaceuticals, Inc.
Nasdaq	NVCR	NovoCure Limited
Nasdaq	OPTN	OptiNose, Inc.
Nasdaq	PRQR	ProQR Therapeutics N.V.
Nasdaq	QTRX	Quanterix Corporation
Nasdaq	SLDB	Solid Biosciences Inc.
Nasdaq	TECH	Bio-Techne Corp

About Nasdaq Global Indexes
Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

Media Relations Contact
Emily Pan
(646) 637-3964
emily.pan@nasdaq.com

Issuer & Investor Contact
Index Client Services
indexservices@nasdaq.com

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG-

FAQ

What are the new additions to Nasdaq's Biotechnology Index in December 2020?

The Nasdaq Biotechnology Index will add 100 new securities including Arbutus Biopharma, Adaptimmune Therapeutics, and BioNTech.

When will the changes to the Nasdaq Biotechnology Index take effect?

The changes will become effective prior to market open on December 21, 2020.

Which companies are being removed from the Nasdaq Biotechnology Index?

Companies removed include ADMA Biologics, Myris, and Gritstone Oncology.

How does the reconstitution of the Nasdaq Biotechnology Index affect investors?

The reconstitution aims to improve market representation, but may cause volatility for stocks being removed.

What is the significance of the Nasdaq Biotechnology Index reconstitution?

It helps reflect current market trends and provides investors with updated insights into the biotech sector.